

Miles A Kirchin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/384632/publications.pdf>

Version: 2024-02-01

51
papers

3,004
citations

172457

29
h-index

189892

50
g-index

51
all docs

51
docs citations

51
times ranked

2051
citing authors

#	ARTICLE	IF	CITATIONS
1	Doseâ€‘Lowering in Contrastâ€‘Enhanced <scp>MRI</scp> of the Central Nervous System: Aâ€‘Retrospective, Parallelâ€‘Group Comparison Using Gadobenate Dimeglumine. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 1660-1675.	3.4	3
2	Gadolinium Clearance in the First 5â€‘Weeks After Repeated Intravenous Administration of Gadoteridol, Gadoterate Meglumine, and Gadobutrol to rats. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 1636-1644.	3.4	8
3	The TRUTH confirmed: validation of an intraindividual comparison of gadobutrol and gadoteridol for imaging of glioblastoma using quantitative enhancement analysis. <i>European Radiology Experimental</i> , 2021, 5, 46.	3.4	0
4	Interaction of macrocyclic gadolinium-based MR contrast agents with Type I collagen. Equilibrium and kinetic studies. <i>Dalton Transactions</i> , 2020, 49, 14863-14870.	3.3	7
5	Macrocyclic MR contrast agents: evaluation of multiple-organ gadolinium retention in healthy rats. <i>Insights Into Imaging</i> , 2020, 11, 11.	3.4	30
6	Gadolinium retention and clearance after administration of macrocyclic magnetic resonance contrast agents to rats. <i>Pediatric Radiology</i> , 2019, 49, 1110-1111.	2.0	6
7	Non-clinical assessment of safety and gadolinium deposition after cumulative administration of gadobenate dimeglumine (MultiHance Â®) to neonatal and juvenile rats. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 92, 268-277.	2.7	16
8	Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 746-752.	3.4	90
9	Low radiation dose in computed tomography: the role of iodine. <i>British Journal of Radiology</i> , 2017, 90, 20170079.	2.2	46
10	Pharmacokinetics of gadobenate dimeglumine in children 2 to 5 years of age undergoing MRI of the central nervous system. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 1096-1103.	3.4	3
11	The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study). <i>American Journal of Neuroradiology</i> , 2015, 36, 1589-1598.	2.4	21
12	Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3â€‘5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol. <i>American Journal of Roentgenology</i> , 2015, 205, 469-478.	2.2	53
13	Low-dose gadobenate dimeglumine-enhanced MRI of the kidney for the differential diagnosis of localized renal lesions. <i>Radiologia Medica</i> , 2015, 120, 1100-1111.	7.7	6
14	Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHanceÂ®) in children. <i>Pediatric Radiology</i> , 2013, 43, 202-211.	2.0	30
15	Lowering Radiation Exposure in CT Angiography Using Automated Tube Potential Selection and Optimized Iodine Delivery Rate. <i>American Journal of Roentgenology</i> , 2013, 200, W628-W634.	2.2	22
16	Gadobenate Dimeglumine (Multihance) in Mr Angiography: An In-Vitro Phantom Comparison with Gadopentetate Dimeglumine (Magnevist) at Different Concentrations. <i>Acta Radiologica</i> , 2012, 53, 1112-1117.	1.1	8
17	Low-Dose Multidetector CT Angiography in the Evaluation of Infrarenal Aorta and Peripheral Arterial Occlusive Disease. <i>Radiology</i> , 2012, 263, 287-298.	7.3	56
18	Contrast-enhanced MRA of the renal and aorto-iliac-femoral arteries: Comparison of gadobenate dimeglumine and gadofosveset trisodium. <i>European Journal of Radiology</i> , 2011, 77, 358-368.	2.6	10

#	ARTICLE	IF	CITATIONS
19	Solid Hypervascular Liver Lesions. <i>Investigative Radiology</i> , 2011, 46, 225-239.	6.2	74
20	Solid Focal Liver Lesions: Dynamic and Late Enhancement Patterns with the Dual Phase Contrast Agent Gadobenate Dimeglumine. <i>Journal of Gastrointestinal Cancer</i> , 2010, 41, 221-232.	1.3	22
21	Multicenter, Double-Blind, Randomized, Intraindividual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine for MR Angiography of Peripheral Arteries. <i>Radiology</i> , 2010, 255, 988-1000.	7.3	42
22	High-Resolution Steady State Magnetic Resonance Angiography of the Carotid Arteries: Are Intravascular Agents Necessary?. <i>Investigative Radiology</i> , 2009, 44, 784-792.	6.2	23
23	Contrast-Enhanced MR Mammography: Improved Lesion Detection and Differentiation with Gadobenate Dimeglumine. <i>American Journal of Roentgenology</i> , 2008, 191, 1339-1346.	2.2	43
24	Gadobenate Dimeglumine as a Contrast Agent for Dynamic Breast Magnetic Resonance Imaging. <i>Investigative Radiology</i> , 2008, 43, 236-242.	6.2	27
25	Intra-individual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine for Contrast-Enhanced Magnetic Resonance Angiography of the Supraaortic Vessels at 3 Tesla. <i>Investigative Radiology</i> , 2008, 43, 695-702.	6.2	27
26	Diagnostic Performance of Gadobenate Dimeglumine-enhanced MR Angiography of the Iliofemoral and Calf Arteries: A Large-Scale Multicenter Trial. <i>American Journal of Roentgenology</i> , 2007, 189, 1223-1237.	2.2	24
27	Gadobenate dimeglumine-enhanced MR angiography: Diagnostic performance of four doses for detection and grading of carotid, renal, and aortoiliac stenoses compared to digital subtraction angiography. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 26, 1020-1032.	3.4	19
28	Improving lesion detection and visualization: implications for neurosurgical planning and follow-up. <i>Neuroradiology</i> , 2007, 49, S27-S34.	2.2	4
29	Enhancing Lesions of the Brain. <i>Academic Radiology</i> , 2006, 13, 744-751.	2.5	26
30	Intraindividual Comparison of Gadobenate Dimeglumine and Gadobutrol for Cerebral Magnetic Resonance Perfusion Imaging at 1.5 T. <i>Investigative Radiology</i> , 2006, 41, 256-263.	6.2	52
31	Safety characteristics of gadobenate dimeglumine: Clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine. <i>Journal of Magnetic Resonance Imaging</i> , 2006, 24, 1378-1385.	3.4	43
32	Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children. <i>Pediatric Radiology</i> , 2005, 35, 501-510.	2.0	40
33	Breast Lesion Detection and Characterization at Contrast-enhanced MR Mammography: Gadobenate Dimeglumine versus Gadopentetate Dimeglumine. <i>Radiology</i> , 2005, 237, 45-56.	7.3	80
34	Contrast-enhanced MR Angiography of the Renal Arteries: Blinded Multicenter Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine. <i>Radiology</i> , 2005, 234, 399-408.	7.3	80
35	Accurate Differentiation of Focal Nodular Hyperplasia from Hepatic Adenoma at Gadobenate Dimeglumine-enhanced MR Imaging: Prospective Study. <i>Radiology</i> , 2005, 236, 166-177.	7.3	340
36	Primary and Secondary Brain Tumors at MR Imaging: Bicentric Intraindividual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine. <i>Radiology</i> , 2004, 230, 55-64.	7.3	90

#	ARTICLE	IF	CITATIONS
37	Contrast-enhanced MR angiography of the run-off vasculature: Intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine. <i>Journal of Magnetic Resonance Imaging</i> , 2003, 17, 694-702.	3.4	82
38	Gadobenate Dimeglumine-Enhanced MRI of the Breast: Analysis of Dose Response and Comparison with Gadopentetate Dimeglumine. <i>American Journal of Roentgenology</i> , 2003, 181, 663-676.	2.2	68
39	Contrast Agents for Magnetic Resonance Imaging. <i>Topics in Magnetic Resonance Imaging</i> , 2003, 14, 426-435.	1.2	155
40	Low-Dose Gadobenate Dimeglumine Versus Standard Dose Gadopentetate Dimeglumine for Contrast-Enhanced Magnetic Resonance Imaging of the Liver. <i>Investigative Radiology</i> , 2003, 38, 85-94.	6.2	100
41	Pharmacokinetics and Safety of Gadobenate Dimeglumine (MultiHance) in Subjects With Impaired Liver Function. <i>Investigative Radiology</i> , 2002, 37, 299-308.	6.2	30
42	Focal Nodular Hyperplasia: Morphologic and Functional Information from MR Imaging with Gadobenate Dimeglumine. <i>Radiology</i> , 2001, 221, 731-739.	7.3	139
43	Detection of Intracranial Metastases. <i>Investigative Radiology</i> , 2001, 36, 72-81.	6.2	62
44	Phase III, randomized, double-blind, cross-over comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2001, 45, 457-463.	0.6	29
45	Safety assessment of gadobenate dimeglumine (MultiHance®): Extended clinical experience from phase I studies to post-marketing surveillance. <i>Journal of Magnetic Resonance Imaging</i> , 2001, 14, 281-294.	3.4	81
46	Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: Effect of dose on lesion detection and delineation. <i>Journal of Magnetic Resonance Imaging</i> , 2001, 14, 525-539.	3.4	46
47	Evaluation of the Accuracy of Gadobenate Dimeglumine-Enhanced MR Imaging in the Detection and Characterization of Focal Liver Lesions. <i>American Journal of Roentgenology</i> , 2000, 175, 1111-1120.	2.2	88
48	Focal Liver Lesions: Evaluation of the Efficacy of Gadobenate Dimeglumine in MR Imaging—A Multicenter Phase III Clinical Study. <i>Radiology</i> , 2000, 215, 727-736.	7.3	188
49	Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. <i>Academic Radiology</i> , 1999, 6, 282-291.	2.5	194
50	MultiHance clinical pharmacology: Biodistribution and MR enhancement of the liver. <i>Academic Radiology</i> , 1998, 5, S86-S89.	2.5	72
51	Gadobenate Dimeglumine (Gd-BOPTA). <i>Investigative Radiology</i> , 1998, 33, 798-809.	6.2	199